Smorodin E P, Kurtenkov O A, Sergeyev B L, Chuzmarov V I, Afanasyev V P
Department of Oncology & Immunology, National Institute for Health Development, Tallinn, Estonia.
Exp Oncol. 2007 Mar;29(1):61-6.
Earlier we found two unusual IgG-antibody specificities to GalNAc beta and GalNAc beta1-3GalNAc beta (para-Forssman disaccharide, PFdi) carbohydrate ligands in human serum. The aim of the study was to evaluate whether elevated antibody levels are related to the progression of gastrointestinal cancer and the histopathological grading.
Specific IgG levels were tested in 159 patients with gastric cancer, 88 patients with colorectal cancer and 96 blood donors by the ELISA using synthetic polyacrylaamide (PAA) conjugates, GalNAc beta-PAA and PFdi-PAA. Biochemical and haematological analyses were performed using automatic equipment.
The anti-PFdi IgG levels were significantly higher in patients with gastric and colorectal cancer than in donors: in stages II-IV, P = 0.0002 - 0.04 (U-test). The elevated anti-PFdi IgG level was associated with the advanced gastric cancer: in stages II, III, IV vs stage I (P = 0.004 - 0.06) and in case of the tumor size T2 + T3 vs T1 (stages I, II; P = 0.03). Differences in anti-GalNAc beta IgG level were insignificant. No relation between antibody levels and the regional and distant metastases of gastric or colorectal cancer was found. The lower anti-GalNAc beta IgG level was associated with lower-differentiated carcinomas (P = 0.01 - 0.04). Prolonged postoperative changes in the levels of both antibodies during the follow-up were established. An elevation of both antibody levels in patients with gastrointestinal cancer was revealed after a surgical removal of G3-tumors (P = 0.003 - 0.01). The anti-PFdi IgG levels correlated with the levels of the C-reactive protein: r = 0.50, P = 0.003. The anti-GalNAc beta IgG levels correlated with the percentage of peripheral blood monocytes: r = 0.42, P = 0.002.
The association of the anti-PFdi IgG level with cancer progression suggests the implication of antibodies in the pathogenesis of gastrointestinal cancer. Further studies are required to identify natural targets of antibodies, their relation to other diseases, prognostic significance in cancer.
此前我们在人血清中发现了两种针对N-乙酰半乳糖胺β（GalNAcβ）和N-乙酰半乳糖胺β1-3N-乙酰半乳糖胺β（对福斯曼二糖，PFdi）碳水化合物配体的异常IgG抗体特异性。本研究的目的是评估抗体水平升高是否与胃肠道癌的进展及组织病理学分级有关。
采用合成聚丙烯酰胺（PAA）偶联物GalNAcβ-PAA和PFdi-PAA，通过ELISA法检测159例胃癌患者、88例结直肠癌患者和96名献血者的特异性IgG水平。使用自动设备进行生化和血液学分析。
胃癌和结直肠癌患者的抗PFdi IgG水平显著高于献血者：在II-IV期，P = 0.0002 - 0.04（U检验）。抗PFdi IgG水平升高与进展期胃癌相关：在II、III、IV期与I期相比（P = 0.004 - 0.06），以及肿瘤大小为T2 + T3与T1相比（I、II期；P = 0.03）。抗GalNAcβ IgG水平的差异不显著。未发现抗体水平与胃癌或结直肠癌的区域及远处转移之间存在关联。抗GalNAcβ IgG水平较低与低分化癌相关（P = 0.01 - 0.04）。随访期间确定了两种抗体水平的术后长期变化。胃肠道癌患者在手术切除G3肿瘤后，两种抗体水平均升高（P = 0.003 - 0.01）。抗PFdi IgG水平与C反应蛋白水平相关：r = 0.50，P = 0.003。抗GalNAcβ IgG水平与外周血单核细胞百分比相关：r = 0.42，P = 0.002。
抗PFdi IgG水平与癌症进展的关联提示抗体参与了胃肠道癌的发病机制。需要进一步研究以确定抗体的天然靶点、它们与其他疾病的关系以及在癌症中的预后意义。
Zotero 插件